4971 results for "Psychedelics"
Population pharmacokinetic-pharmacodynamic modeling of co-administered N,N-dimethyltryptamine and harmine in healthy subjects.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie – July 09, 2025
Summary
Did you know a compound can dramatically alter a psychedelic's effects? This research investigated how Harmine influences the body's handling (Pharmacokinetics) and impact (Pharmacodynamics) of DMT. Sixteen healthy participants received various doses. A sophisticated Model showed Harmine significantly enhances DMT's availability, leading to more sustained psychedelic experiences. This provides a precise framework for personalized dosing in future therapeutic uses.
Abstract
N,N-dimethyltryptamine (DMT) is a psychedelic compound commonly co-administered with the monoamine oxidase inhibitor harmine in ayahuasca-inspired ...
Structure–Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice
ACS Pharmacology & Translational Science – November 02, 2022
Summary
Only specific tryptamines, like the tertiary amine psilocybin, act as potent psychedelics. In drug studies, psilocybin and its active form psilocin, an agonist at the 5-HT receptor, induced psychedelic-like head twitches in mice (ED50 0.11-0.29 mg/kg). Other related tryptamines, despite their chemistry showing nanomolar affinity for serotonin receptors, lacked this hallucinogen effect. This pharmacology highlights how subtle chemical differences in these compounds dictate their neurotransmitter receptor influence on behavior, revealing critical insights for future psychedelic research.
Abstract
4-Phosphoryloxy-N,N-dimethyltryptamine (psilocybin) is a naturally occurring tertiary amine found in many mushroom species. Psilocybin is a prodrug...
Underground MDMA-, LSD- and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary
Drug Science Policy and Law – March 24, 2015
Summary
Underground psychedelic-assisted psychotherapy has thrived in Europe, even after the prohibition of MDMA and LSD. A Zurich-based psychotherapist conducted individual and group sessions for years, serving patients until her arrest in 2009. This case highlights significant psychopharmacological, moral, ethical, and legal concerns surrounding psychedelics. Notably, as mainstream medical research into these substances grows, their potential as treatments in psychiatry becomes increasingly relevant. The evolving landscape reflects a shift in attitudes towards psychedelics in psychology and drug studies.
Abstract
Underground psychedelic-assisted psychotherapy has persisted in Europe despite the banning of the substances LSD and MDMA in the 1960s and 1980s, r...
Psilocybin for depression: Considerations for clinical trial design
Journal of Psychedelic Studies – September 01, 2019
Summary
Addressing major depressive disorder’s enormous global burden, rigorous clinical trial design is crucial for novel antidepressant medicine like psilocybin. This protocol outlines critical research design elements for psychedelic drug studies, emphasizing careful participant selection and blinding. It details considerations for dosing regimens and psychological intervention, ensuring high standards in clinical psychology and psychiatry. Such meticulous clinical study design is vital for generating reproducible results, advancing our understanding of neurotransmitter receptor influence on behavior and chemical synthesis alkaloids, ultimately broadening acceptance for this promising treatment in medicine.
Abstract
Background and aims Given the enormous global burden of depressive illness, there is an urgent need to develop novel and more effective treatments ...
A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy.
Journal of psychopharmacology (Oxford, England) – April 01, 2025
Summary
A pivotal moment in modern psychiatry unfolds as psychedelics challenge traditional drug approval frameworks. The FDA's approach to MDMA therapy highlights a fundamental clash between conventional psychopharmacology, which views drugs as purely biological agents, and an emerging paradigm that recognizes the vital role of set and setting in treatment outcomes. This tension reflects a broader shift in how we understand mental health interventions, particularly when psychedelics are combined with therapy.
Abstract
The recent rejection of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy by the U.S. Food and Drug Administration (FDA) is a dramatic mome...
Safety, Pharmacokinetics, and Pharmacodynamics of a 6-h N,N-Dimethyltryptamine (DMT) Infusion in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Trial.
Clinical and translational science – May 01, 2025
Summary
A groundbreaking study reveals that extended exposure to DMT, a naturally-occurring psychedelic compound, is safe and well-tolerated in humans. Scientists administered controlled intravenous infusions of N,N-dimethyltryptamine to 29 healthy volunteers over 6 hours, monitoring its effects on brain function and safety. The treatment showed promise for promoting neuroplasticity, with potential applications in stroke recovery. Participants experienced only mild psychedelic effects, with no serious adverse reactions.
Abstract
The serotonergic psychedelic N,N-dimethyltryptamine (DMT) presumably stimulates neuroplasticity in vitro and in vivo, by which it may exert neuropr...
Ayahuasca-inspired DMT/HAR formulation reduces brain differentiation between self and other faces.
NeuroImage – June 01, 2025
Summary
Psychedelics like ayahuasca can blur the line between self and other - now scientists know why. Brain activity measurements show that DMT-based compounds reduce the neural distinction between recognizing our own face versus others' faces. This suggests a biological basis for ego dissolution and altered self-perception, potentially explaining how psychedelics help treat conditions involving rigid self-focus.
Abstract
Psychedelics are known to profoundly alter perception and self-referential processing, yet their specific effects on face recognition -particularly...
"This is you teaching you:" Exploring providers' perspectives on experiential learning and enhancing patient safety and outcomes in ketamine-assisted therapy.
PloS one – January 01, 2024
Summary
Personal experience with psychedelics significantly enhances therapists' ability to support patients during ketamine therapy, according to healthcare providers at leading wellness clinics. Through in-depth interviews with eight trained therapists, researchers found that firsthand psychedelic experience helped practitioners better understand their clients' journeys and build stronger therapeutic relationships. Providers emphasized that formal experiential training would improve patient safety and treatment outcomes.
Abstract
This study explores therapists' perspectives on experiential learning, competencies, and training in ketamine-assisted therapy (KAT), a form of psy...
Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines
Frontiers in Pharmacology – February 09, 2022
Summary
Synthetic phenethylamine compounds, related to the psychedelic mescaline, interact with brain receptors up to 63 times more strongly than mescaline itself. Researchers investigated various scalines and 3C-scalines to understand how these derivatives affect serotonin receptors. They found that modifying these compounds, especially through fluorination, significantly improved their binding and activation of 5-HT2A and 5-HT2C receptors, crucial for psychedelic effects. This suggests a promising path for developing novel therapeutics.
Abstract
3,4,5-Trimethoxyphenethylamine (mescaline) is a psychedelic alkaloid found in peyote cactus. Related 4-alkoxy-3,5-dimethoxy-substituted phenethylam...
Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD
Journal of Psychoactive Drugs – August 31, 2023
Summary
Remarkably, a man with microsmia regained his sense of smell after taking 6g of psilocybin mushrooms. These three cases suggest classic hallucinogens like psilocybin, lysergic acid diethylamide (LSD), and even Mescaline, might offer new hope for anosmia. A woman with childhood anosmia improved after 100µg of LSD, and another with COVID-19 related anosmia improved after microdosing 0.1g of psilocybin. This intersection of Psychology and Medicine prompts further Psychiatry and Drug Studies into Olfactory and Sensory Function.
Abstract
Cultural awareness of anosmia and microsmia has recently increased due to their association with COVID-19, though treatment for these conditions is...
Supplementary material for: Regional specificity of the cingulate cortex thickness association with the intensity of psilocybin experience: a replication study
Zenodo (CERN European Organization for Nuclear Research) – December 13, 2025
Summary
A compelling neuroscience finding reveals that the spatial organization of the cingulate cortex strongly predicts psilocybin's effects on consciousness. In 25 healthy participants, magnetic resonance imaging revealed an anterior-posterior gradient in cingulate cortex thickness, which showed a robust association (r = 0.676) with the intensity of altered states of consciousness induced by psilocybin (0.26 mg/kg). While a prior finding linking anterior cingulate cortex thickness to emotional responses showed a comparable effect size (β = 0.523) in this replication, it lacked statistical significance. This psychology research highlights brain mapping of the cortex.
Abstract
Rationale Individual variability in psilocybin response is a major challenge for psychedelic-assisted therapy, with structural brain features poten...
Ayahuasca Retreats: The Role of Awe and Mystical Experiences in Well-Being.
Journal of psychoactive drugs – April 16, 2025
Summary
Profound mystical experiences during ayahuasca retreats can significantly impact well-being, but not always in expected ways. Researchers tracked 60 participants who attended legal retreats, finding that the most positive outcomes occurred when people reported deep mystical experiences without feeling overwhelmed by the vastness of their psychedelic journey. This suggests that balanced, manageable experiences may be key to transformation.
Abstract
Research on the positive psychological effects of psychedelics has surged since the early 2000s, particularly regarding increased well-being. Studi...
Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach.
Frontiers in psychiatry – January 01, 2025
Summary
MDMA's unique ability to enhance empathy and trust may offer breakthrough treatment for pathological narcissism. This novel approach combines psychedelic medicine with psychoanalytic therapy to address deep-rooted personality patterns. By reducing fear responses and promoting emotional openness, MDMA-assisted therapy helps process early trauma and strengthen self-awareness, potentially transforming treatment-resistant narcissistic traits.
Abstract
Pathological narcissism (PN) is a complex, treatment-resistant disorder characterized by unstable self-esteem that fluctuates between grandiosity a...
Assessment of the acute effects of 2C-B vs psilocybin on subjective experience, mood and cognition
OpenAlex – February 16, 2023
Summary
A compelling finding reveals the hallucinogen 2C-B, derived from mescaline, offers a "lighter" psychedelic experience than psilocybin. In a study of 22 healthy participants, 2C-B produced psychedelic states, but psilocybin led to larger dysphoria, subjective impairment, and auditory alterations, impacting mood and cognition. Both compounds, compared to placebo, caused equivalent psychomotor slowing and spatial memory issues. This work in psychology and drug studies advances understanding of how these substances, influencing neurotransmitter receptors, affect behavior.
Abstract
Abstract 2,5-dimethoxy-4-bromophenethylamine (2C-B) is a hallucinogenic phenethylamine derived from mescaline. Observational and preclinical data h...
Acute Effects of 2C-E in Humans: An Observational Study
Frontiers in Pharmacology – March 18, 2020
Summary
The novel hallucinogen 2C-E, structurally akin to mescaline, profoundly alters perception and elevates euphoric mood. An observational study with ten psychedelic users demonstrated that oral administration of 2C-E, acting as a serotonin receptor agonist, reached peak saliva concentrations within two hours. This pharmacology, critical for Psychedelics and Drug Studies, highlights its influence on mood and behavior. Understanding its pharmacokinetics is vital for Medicine and Forensic Toxicology and Drug Analysis, especially concerning addiction and neurotransmitter receptor influence.
Abstract
2,5-Dimethoxy-4-ethylphenethylamine (2C-E) is psychedelic phenylethylamine, with a chemical structure similar to mescaline, used as new psychoactiv...
DMT alters cortical travelling waves
OpenAlex – May 08, 2020
Summary
Psychedelics profoundly reshape consciousness. N,N-Dimethyltryptamine (DMT), a serotonergic compound, robustly alters brain activity, revealing patterns akin to visual stimulation. Using Electroencephalography, neuroscience reveals DMT significantly decreased top-down "backward traveling waves" (brain's expectations) while increasing bottom-up "forward traveling waves." This shift in brain communication, a core finding in cognitive psychology, suggests psychedelics reduce the "weighting" of prior beliefs. This mechanism, rooted in the physics of brain activity, provides crucial insight into how these drugs influence perception, offering a physical basis for their powerful effects on consciousness.
Abstract
Abstract Psychedelic drugs are potent modulators of conscious states and therefore powerful tools for investigating their neurobiology. N,N, Dimeth...
Time-resolved Neural and Experience Dynamics of Medium- and High-dose N,N-Dimethyltryptamine.
Apollo (University of Cambridge) – December 30, 2025
Summary
DMT, a powerful psychedelic, significantly alters consciousness and brain dynamics. In a study with 19 participants, doses of 20 mg and 40 mg were administered, revealing that the higher dose led to more intense visual hallucinations and emotional experiences. Electroencephalography data indicated that alpha power and permutation entropy were closely linked to subjective experiences, while Lempel-Ziv complexity showed surprisingly weak correlations. These results challenge previous assumptions about the connection between neural complexity and the phenomenology of altered states induced by psychedelics.
Abstract
N,N-dimethyltryptamine (DMT) is a fast-acting psychedelic drug that induces a radical reorganization of conscious contents and brain dynamics. Howe...
Time-resolved Neural and Experience Dynamics of Medium- and High-dose N,N-Dimethyltryptamine
Journal of Cognitive Neuroscience – December 30, 2025
Summary
DMT, a powerful psychedelic, drastically alters conscious experience and brain dynamics. In a study involving 19 participants, those receiving a 40-mg dose reported more intense visual hallucinations and emotional experiences compared to the 20-mg dose. Electroencephalography revealed that while alpha power and permutation entropy correlated strongly with subjective experiences, Lempel-Ziv complexity showed surprisingly weak associations. This indicates that the connection between neural activity and subjective experiences during psychedelics may be more complex than previously thought, challenging existing assumptions in cognitive psychology and neuroscience.
Abstract
N,N-dimethyltryptamine (DMT) is a fast-acting psychedelic drug that induces a radical reorganization of conscious contents and brain dynamics. Howe...
CURRENT STATE OF PSILOCYBIN-ASSISTED THERAPY IN MOOD DISORDERS
Psychiatria Danubina – July 17, 2024
Summary
Psilocybin-assisted therapy presents a compelling new direction for treating mood disorders in Psychiatry. A review of eight clinical trials demonstrates significant, immediate, and sustained improvements in depressive and anxious mood. Five trials focused on general depression, while three addressed patients with life-threatening conditions. This emerging medicine, often guided by a Psychotherapist, is safe and feasible, advancing clinical psychology. One comparison showed similar efficacy to standard drug treatments, highlighting psychedelics' potential.
Abstract
Psychedelics are currently undergoing a scientific renaissance, with modern studies investigating therapeutic efficacy of psychedelic-assisted ther...
High-resolution tracking of unconfined zebrafish behavior reveals stimulatory and anxiolytic effects of psilocybin
Molecular Psychiatry – January 17, 2024
Summary
A compelling Neuroscience finding reveals the hallucinogen Psilocybin acts as an anxiolytic. In larval zebrafish, a model for Psychedelics and Drug Studies, it facilitated exploration and prevented stress responses. This research, crucial for Psychology, shows psilocybin inhibits serotonin neurons in the dorsal raphe nucleus. Understanding this serotonergic neurotransmitter receptor influence on behavior, like insights from Nicotinic Acetylcholine Receptors Study, is vital for drug development to potentially avoid issues like desensitization.
Abstract
Abstract Serotonergic psychedelics are emerging therapeutics for psychiatric disorders, yet their underlying mechanisms of action in the brain rema...
Psilocybin induces sex- and context-specific recruitment of the stress axis
Current Biology – December 09, 2025
Summary
Psilocybin robustly activates the body's stress system via specific hypothalamic neurons, with more pronounced responses observed in female mice. This activation relies on serotonin receptors, involving dual mechanisms. Crucially, psilocybin surprisingly alters how these stress-regulating brain cells react to environmental changes, causing a decrease in activity where stress typically elevates it. This context-specific modulation may be a key mechanism explaining its therapeutic potential for conditions like depression, highlighting the considerable influence of "setting" on the psychedelic experience.
Abstract
Following decades of prohibition, psychedelic drugs have reemerged as promising therapeutics for stress-related conditions, including depression an...
use of psilocybin in the treatment of psychiatric disorders – review
Journal of Education Health and Sport – August 15, 2023
Summary
Psilocybin, a classic hallucinogen, demonstrates significant promise in modern Psychiatry. Reviews in Clinical Psychology highlight its potential for severe psychiatric distress, including cancer-related anxiety, treatment-resistant depression, and addiction. Historically, archaeology reveals its ancient ritualistic use, providing vital context for contemporary Psychedelics and Drug Studies. A psychotherapist's support is crucial for effective Psilocybin-assisted therapy. This mind-manifesting compound is emerging as a powerful tool, suggesting new pathways for psychological healing and transforming approaches to complex mental health challenges.
Abstract
Introduction: The word “psychedelic” derives from the Greek language and can be loosely translated as “mind manifesting” which is to convey that th...
Human brain changes after first psilocybin use
OpenAlex – October 14, 2024
Summary
A single 25mg dose of the hallucinogen psilocybin profoundly alters the human brain, yielding lasting benefits. In a Drug Studies investigation with 28 psychedelic-naive individuals, anatomical and functional brain changes persisted for up to one month. Neuroscience revealed more integrated brain networks, correlating with improved well-being and psychological insight. This suggests psilocybin's potential in Mental Health and Psychiatry, enhancing cognitive flexibility. These effects were exclusive to the 25mg dose, underscoring psilocybin's specific impact on psychology.
Abstract
ABSTRACT Psychedelics have robust effects on acute brain function and long-term behavior but whether they also cause enduring functional and anatom...
Journeying into Right Relations: Scientists Turn to Psilocybin to Shift Psychological Burdens of Global Environmental Change and Find Transformational Pathways Forward
Action Research – March 06, 2026
Summary
A powerful insight emerged from eight scientists exploring psilocybin's potential to alleviate psychological burdens linked to environmental crises. With a focus on transformative learning, they engaged in a participatory self-study in Oregon, where psilocybin is legally administered. Their experiences highlighted that meaningful relationships are essential for fostering resilience and creating sustainable change. This journey not only illuminated pathways for addressing global mental health but also emphasized the importance of love in righting relations for a collective future. Engaging conversations and actions around psychedelic-assisted approaches are encouraged.
Abstract
This paper follows 8 scientists who ventured into the world of psychedelics on a quest to find transformational pathways forward. Each have worked ...
Do Drugs Have Religious Import? A 40-Year Retrospective
Journal of Humanistic Psychology – April 01, 2004
Summary
A leading scholar's four-decade reflection illuminates how psychedelic experiences have profoundly shaped religious traditions, from ancient Vedic and Eleusinian mysteries to the contemporary Native American Church. Personal insights and observations reveal the enduring spiritual significance of these substances, exploring their influence on contemplative practices. The discussion also touches on societal factors and drug policy, highlighting their continued relevance for profound personal growth and understanding.
Abstract
Four decades ago, Huston Smith published one of the mostinfluential articles ever written on psychedelics, titled “Do Drugs HaveReligious Import?” ...
Teacher plants - Indigenous Peruvian-Amazonian dietary practices as a method for using psychoactives.
Journal of ethnopharmacology – March 25, 2022
Summary
No Summary
Abstract
Indigenous groups of the Amazon have developed intricate methods for the application of psychoactives, among which particularly the dieta or diet m...
Activity-Dependent Neural Rewiring: Mechanisms of Psilocybin-Induced Cortical Network Reorganization
Zenodo (CERN European Organization for Nuclear Research) – February 06, 2026
Summary
Psilocybin has shown significant promise in treating mental health disorders by promoting structural neural plasticity. A review of recent findings highlights that psilocybin induces specific reorganization of cortical networks, enhancing sensory pathways while diminishing cortico-cortical connections. Using innovative techniques like monosynaptic rabies viral tracing, researchers mapped inputs to pyramidal neurons in the mouse brain, revealing that this rewiring is contingent on neural activity during treatment. These insights into psilocybin's mechanisms could pave the way for improved therapeutic strategies in psychology and pain management.
Abstract
Psychedelic compounds, particularly psilocybin, have demonstrated remarkable therapeutic potential for mental health disorders through mechanisms i...
Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals.
Scientific reports – November 14, 2024
Summary
Healthcare providers show strong support for psychedelic therapy, with psilocybin and MDMA gaining acceptance as promising treatments. In a survey of 879 medical professionals, most believed in these hallucinogens' therapeutic potential, particularly for depression and PTSD. While attitudes were positive, knowledge gaps exist about clinical applications and safety protocols.
Abstract
Psychedelic-assisted therapy (PAT) with substances like psilocybin and MDMA has shown promise for conditions including depression and post-traumati...
Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants
The International Journal of Neuropsychopharmacology – November 04, 2022
Summary
A compelling finding: the medicine Ketanserin can dramatically shorten the effects of the hallucinogen Lysergic acid diethylamide (LSD). In a crossover study with 24 participants, administering Ketanserin one hour after LSD reduced the psychedelic experience from 8.5 hours (with placebo) to just 3.5 hours. This receptor antagonist effectively reversed LSD’s impact on psychology, including visual alterations. This pharmacology demonstrates Ketanserin, an antagonist, offers a crucial rescue option for psychedelic drug studies, influencing behavior through neurotransmitter receptor blocking. Biochemical analysis revealed no change in BDNF levels.
Abstract
Abstract Background Lysergic acid diethylamide (LSD) is currently being investigated in psychedelic-assisted therapy. LSD has a long duration of ac...
Evidence on the impairing effects of Ayahuasca on fear memory reconsolidation.
Psychopharmacology – October 01, 2022
Summary
A breakthrough in PTSD treatment may lie in Ayahuasca's ability to modify fear memories. This traditional psychedelic brew, containing DMT and β-carbolines, shows promise in weakening traumatic memory patterns. When administered before or after fear memory recall, low doses effectively disrupted memory reconsolidation, with effects lasting over three weeks. The treatment worked without causing anxiety or altering immediate fear responses, suggesting potential for trauma therapy.
Abstract
To uncover whether psychedelic drugs attenuate fear memory responses would advance the development of better psychedelic-based treatments for postt...
The Consumption of Psychoactive Plants in Ancient Global and Anatolian Cultures During Religious Rituals: The Roots of the Eruption of Mythological Figures and Common Symbols in Religions and Myths
NeuroQuantology – May 31, 2014
Summary
Visions from ancient psychedelic plant consumption profoundly shaped global mythology. For centuries, a vast array of cultures, from Aztec to Hellenic, engaged in ritualistic consumption of psychoactive plants like psilocybin and ibogaine. These powerful experiences, central to ancient history and drug studies, generated vivid illusions. The aesthetics of these "plant trips" directly influenced the creation of countless mythological characters, gods, and demons, impacting literature and religious narratives across numerous societies. This fundamental link between psychedelics and the bedrock of human storytelling remains widely underestimated.
Abstract
Psychoactive plants which contain hallucinogenic molecules that induce a form of altered states of consciousness (H-ASC) have been widely used duri...
Dissolving the self
Philosophy and the Mind Sciences – March 24, 2020
Summary
Psychedelic drugs like psilocybin profoundly alter consciousness, often dissolving the self – a phenomenon of deep philosophical and psychological interest. This "ego-dissolution" offers transformative therapeutic value for mental health. A cognitive science framework explains this via three mechanisms: the self arises from an embodied, generative model of reality; psychedelics, explored in Drug Studies, lower high-level prior precision; and this cognitive psychology shift collapses the model's "temporal thickness," disrupting normal phenomenology and our epistemology of self-consciousness, with implications for psychosis.
Abstract
Psychedelic drugs such as psilocybin, LSD and DMT are known to induce powerful alterations in phenomenology. Perhaps of most philosophical and scie...
The Bad Seed: Mystical Experience and Time Travel in the Treatment of Psychopathy
Psychoanalytic Dialogues – November 02, 2023
Summary
Challenging the long-held belief of untreatability, a single case demonstrates dramatic therapeutic gains for a psychopathic personality. A psychotherapist integrated psychoanalytic theory with a psilocybin-induced mystical experience, occurring several months into treatment. This powerful psychedelic intervention was pivotal. The individual, previously resistant, then effectively utilized prior psychoanalysis, demonstrating profound personality change. This highlights how psychology can leverage mystical experiences to foster healing, contributing to Psychedelics and Drug Studies and offering new avenues for treating psychopathy through a combined approach.
Abstract
Psychopathy has long been considered untreatable. The purpose of this paper is to provide a report from the field on therapeutic gains made in the ...
Millennials in the search for spiritual ecstasy
OpenAlex – October 14, 2021
Summary
Millennials are driving a global revitalization of indigenous spiritual practices, seeking psychedelic plant medicine ceremonies for profound personal growth. Visiting places like Huautla de Jimenez for shamanic mushroom rituals, individuals pursue psychological healing for mental, emotional, and spiritual imbalances. Five common motivations emerged: a search for knowledge, healing, curiosity, self-improvement, and inner wellness. These drug studies highlight the commodification of sacred experiences and the critical need for indigenous inclusion in validating these powerful psychedelics.
Abstract
Although young countercultural travellers and spiritual seekers have visited Latin American indigenous communities for the purposes of drug-induced...
Ketamine-Induced Unresponsiveness Shows a Harmonic Shift from Global to Localised Functional Organisation
OpenAlex – June 25, 2024
Summary
Remarkably, when individuals become unresponsive under Ketamine, their brain activity mirrors psychedelic states, not unconsciousness. Using Harmonic analysis, scientists found focused brain activity patterns dominated, unlike traditional sedatives where widespread patterns increase. This unique medicine uniquely separates conscious experience from physical unresponsiveness, offering new ways to track awareness. Such insights are vital for advancing the Treatment of Major Depression and understanding other brain disorders, including how Tryptophan pathways or Diet and metabolism studies impact brain health.
Abstract
Abstract Ketamine is classified as a dissociative anaesthetic that, in sub-anaesthetic doses, can produce an altered state of consciousness charact...
Sex-specific role of the 5-HT2A receptor in psilocybin-induced extinction of opioid reward.
Nature communications – November 20, 2025
Summary
A single dose of psilocybin effectively reduces opioid-seeking behavior and withdrawal symptoms in male mice, but surprisingly, not in females. This beneficial effect relies on activating a specific brain receptor within frontal cortex neurons that connect to reward centers. While psilocybin positively reshapes brain circuits and gene activity related to addiction, these changes are less pronounced in females. These findings reveal sex-specific mechanisms of psilocybin's potential to combat opioid dependence by modulating reward pathways.
Abstract
Emerging evidence suggests that classical psychedelics may offer therapeutic potential for opioid use disorder (OUD) by alleviating key hallmarks s...
Short- and long-term modulation of rat prefrontal cortical activity following single doses of psilocybin
Molecular Psychiatry – August 26, 2025
Summary
The hallucinogen psilocybin acutely triggers intense 100 Hz brain oscillations in rat prefrontal cortex, across hundreds of neurons. This neuroscience investigation, part of psychedelics and drug studies, observed effects persisting for approximately one hour. Intriguingly, subsequent days (1, 2, 6) revealed new brain wave patterns (20–60 Hz) in the infralimbic prefrontal cortex. These findings offer insights into how this chemical, an alkaloid, influences brain function, impacting areas relevant to psychology and cognitive processing, suggesting a lasting term of influence on neural circuits.
Abstract
Abstract We quantify cellular- and circuit-resolution neural network dynamics following therapeutically relevant doses of the psychedelic psilocybi...
Increased low-frequency brain responses to music after psilocybin therapy for depression
OpenAlex – February 15, 2022
Summary
Psilocybin therapy significantly enhances the brain's emotional response to music. Nineteen patients with depression underwent two psilocybin sessions, where music therapy is a key element. Functional magnetic resonance imaging (fMRI) revealed increased activity in the temporal lobe and supramarginal gyrus during music listening post-treatment, compared to resting state fMRI. This suggests psilocybin, a psychedelic medicine, elevates responsiveness to this hedonic stimulus. These neuroscience findings in psychology highlight how psilocybin influences sensory processing, with activity correlating to subjective drug effects, offering insights for medicine and drug studies.
Abstract
Abstract Psychedelic-assisted psychotherapy with psilocybin is an emerging therapy with great promise for depression, and modern psychedelic therap...
Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals
Journal of Psychopharmacology – June 30, 2021
Summary
A single dose of the hallucinogen psilocybin, a compound from chemical synthesis and alkaloids, significantly impacts brain communication, offering insights for psychology and neuroscience. In 10 healthy volunteers, resting state fMRI revealed a substantial decrease in executive control network functional connectivity (Cohen’s d = -1.73) one week later. This shift predicted increased mindfulness three months on (r = -0.65). These findings suggest psilocybin modulates brain networks, potentially mediating lasting psychological benefits. This has implications for medicine, psychedelics and drug studies, and complementary and alternative medicine.
Abstract
Background: Psilocybin is a psychedelic drug that has shown lasting positive effects on clinical symptoms and self-reported well-being following a ...
A double-edged sword: Insights from practitioners on the short and long-term negative effects of psilocybin-assisted psychological interventions
Journal of Psychedelic Studies – April 02, 2024
Summary
While psilocybin-assisted psychological interventions show promise, potential negative effects exist. Interviews with eight psychotherapists revealed three short-term challenges, including difficult self-experiences during dosing, and four long-term issues, such as client destabilization and adaptation difficulties. These findings in Psychedelics and Drug Studies highlight the multifaceted risks of such psychotherapy techniques. Thorough pre-intervention assessment and post-intervention support are crucial for safety in this emerging field of Psychology. Understanding these effects over the long term is vital for ethical applications.
Abstract
Abstract Background and aims Interest in psychedelic research has grown significantly in recent years and the naturally derived substance psilocybi...
Short- and long-term reconfiguration of rat prefrontal cortical networks following single doses of psilocybin
OpenAlex – December 13, 2024
Summary
Psilocybin, a hallucinogen, acutely unmasks 100Hz high-frequency oscillations within the infralimbic cortex, a key Prefrontal cortex region. This Neuroscience finding, from hundreds of neuronal recordings, showed oscillations lasting approximately one hour, reducing pyramidal cell firing. Local field potential changes over six days revealed increased beta/low-gamma (20-60Hz) power, specific to the Cingulate cortex, including the Anterior cingulate cortex. This work in Psychedelics and Drug Studies advances Psychology's understanding of plasticity, offering biomarkers.
Abstract
SUMMARY We quantify cellular- and circuit-resolution neural network dynamics following therapeutically relevant doses of the psychedelic psilocybin...
Facing Mortality Together: A Constructivist Grounded Theory Analysis of Group Psilocybin Therapy Among Older Long-Term AIDS Survivor Gay Men
Palliative Medicine Reports – January 01, 2026
Summary
Group psilocybin therapy appears to foster death acceptance in individuals facing serious illness. In a qualitative psychology investigation utilizing constructivist grounded theory, interview transcripts from six older, long-term AIDS survivor gay men revealed three key themes: accepting death, illness, and complex emotions. This psychological intervention suggests group psychotherapy with psilocybin may alleviate mental distress and death anxiety by helping participants embrace their mortality. Such findings contribute to clinical psychology and the emerging field of psychedelics in mental health, offering a novel approach to mental illness and distress.
Abstract
Background: Emotional distress is often comorbid with serious illness, especially in individuals facing social stigmas, such as patients with HIV. ...
EFFECT OF ACUTE PSILOCYBIN ON THERMAL AND NEUROPATHIC PAIN IN RODENTS
The International Journal of Neuropsychopharmacology – February 01, 2025
Summary
A compelling neuroscience finding reveals psilocybin, a potent hallucinogen, significantly alleviates neuropathic pain. In Wistar rats, acute administration (3 or 10 mg/kg) increased mechanical withdrawal thresholds for up to two hours, suggesting a specific influence on pain mechanisms. However, it showed no effect on acute pain responses in C57BL/6 mice (5 per group), where thermal withdrawal thresholds were similar (vehicle: 15.6°C; psilocybin: 17.28°C). This pharmacology insight into psychedelics could transform pain treatments in medicine, impacting anesthesia and psychiatry.
Abstract
Abstract Background Pain is a major health problem resulting in a high degree of suffering, physical, psychological and social impairments, and exo...
Psilocybin - new remedy for patients with psychiatric disorders? Critical analysis of the current state of knowledge
Journal of Education Health and Sport – December 30, 2023
Summary
Psilocybin, a potent hallucinogen, offers a safety profile comparable to standard psychiatric medicine. Evidence indicates this psychedelic alkaloid provides clinically meaningful improvements in treating depression—a significant global economic burden—trauma, and obsessive-compulsive disorders. Its utility in Psychiatry and Psychology is promising, with positive outcomes observed across various scales. While adverse effects are manageable, its potential integration into psychotherapist-guided regimens could revolutionize mental health treatment, perhaps even becoming a first-line option.
Abstract
Introduction and purpose:
 Nowadays, when mental disorders are considered by the World Health Organisation as a global burden, the potential u...
Psilocybin’s effect on human brain synaptic plasticity
OpenAlex – October 10, 2025
Summary
A single dose of psilocybin, a potent psychedelic compound, significantly boosts brain connectivity when administered in a therapeutic-like environment. Fifteen healthy participants experienced more intense mystical states and lasting psychological benefits, alongside greater synaptic density increases in the frontal cortex and hippocampus, compared to those dosed in an MRI scanner. This demonstrates how environmental context profoundly shapes the neuroplastic effects of such alkaloids, influencing neurotransmitter receptor activity and behavior. These findings have crucial implications for future drug studies.
Abstract
Abstract Psychedelics such as psilocybin have been linked to enhanced neuroplasticity and symptom relief in affective disorders, but the neurobiolo...
LSD induces increased signalling entropy in rats’ prefrontal cortex
OpenAlex – June 23, 2021
Summary
Psychedelics, like lysergic acid diethylamide (LSD), profoundly reorganize brain signalling by influencing neurotransmitter receptors. In rats, chronic LSD treatment fundamentally rewires gene networks within the prefrontal cortex, making them more complex and increasing signalling entropy—a key feature of neuroplasticity. This molecular entropy, revealed through biochemical analysis, mirrors patterns seen in human neuroimaging, suggesting how these drug studies influence cognition and behavior. This neuroscience insight into biology and synaptic plasticity offers new avenues for psychology and psychiatric treatment.
Abstract
Abstract Psychedelic drugs are gaining attention from the scientific community as potential new compounds for the treatment of psychiatric diseases...
The effect of psilocin on neurotransmitters release in the claustrum and on rat behavior.
Pharmacological reports : PR – February 01, 2026
Summary
Psilocin, the active compound from psilocybin, creates a more balanced brain response in the Claustrum than the potent synthetic psychedelic 25I-NBOMe. Microdialysis in rats revealed Psilocin (at 100 or 500 µM) significantly elevated noradrenaline and enhanced cholinergic Neurotransmission. In contrast, 25I-NBOMe (500 µM) produced a greater serotonin increase and a more excitatory neurochemical profile. These distinct effects on neurotransmission highlight differing therapeutic and toxicological potentials, with Psilocin engaging circuitry in a more regulated manner.
Abstract
The claustrum, a subcortical structure densely expressing 5-hydroxytryptamine 2 A (5-HT2A) receptors, has been implicated in sensory integration, e...
Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol.
Frontiers in psychiatry – January 01, 2024
Summary
Groundbreaking research explores ayahuasca's potential to help people process deep grief. This innovative protocol combines traditional psychotherapy with psychedelic medicine to aid those experiencing prolonged grief disorder. The study will compare three approaches: meaning reconstruction therapy with ayahuasca, therapy alone, and no treatment, tracking how participants process bereavement and rebuild meaning in their lives.
Abstract
Psychotherapy for Prolonged Grief Disorder (PGD), a condition characterized by an intense and persistent grief response, has received increased att...
Novel treatments of depression: bridging the gap in current therapeutic approaches
Exploration of Neuroscience – August 05, 2024
Summary
For many, traditional depression treatments aren't enough. A review explores promising new therapeutic approaches beyond conventional methods. It highlights the potential of glutamatergic modulation, brain stimulation, anti-inflammatory agents, gut-brain axis interventions, gaba modulation, and psychedelic-assisted psychotherapy. These diverse strategies offer significant hope for more effective depression management.
Abstract
Depression poses a significant global health burden, yet current therapeutic approaches focusing on monoaminergic neurotransmission often fall shor...
Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study
European Neuropsychopharmacology – October 17, 2020
Summary
Microdosing with LSD can enhance mood and cognitive performance, as shown in a study with 24 healthy participants. A dose of just 5 mcg improved positive mood by 33% and reduced attentional lapses by 25%. Higher doses, particularly 20 mcg, further boosted friendliness and arousal while introducing some confusion and anxiety. Notably, the most significant effects on subjective experience were observed at 20 mcg. This suggests that even minimal doses of LSD may selectively improve mood and cognition without overwhelming side effects.
Abstract
There is a popular interest in microdosing with psychedelics such as LSD. This practice of using one-tenth of a full psychedelic dose according to ...
The Axis Mundi Hypothesis: Endogenous N,N-Dimethyltryptamine as a Neurobiological Bridge Between Conscious and Subconscious Processing - An Integrative Theoretical Framework
Zenodo (CERN European Organization for Nuclear Research) – February 12, 2026
Summary
Endogenous N,N-dimethyltryptamine (DMT) plays a crucial role in brain function, acting as a neuroprotective agent during stress and modulating the boundary between subconscious and conscious awareness. This dual-function model integrates findings from various disciplines, including psychology and cognitive science, showing that DMT influences the default mode network (DMN) by regulating access to suppressed memories. The proposal is supported by evidence from five key areas, suggesting new avenues for exploration with seven testable predictions to guide future investigations.
Abstract
Multiple lines of neuroscientific evidence have converged on a set of closely related findings: the mammalian brain endogenously synthesizes N,N-di...
Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico.
The American journal of drug and alcohol abuse – September 03, 2023
Summary
Special operations veterans experiencing trauma showed remarkable improvements in mental health after receiving innovative psychedelic therapy. The treatment, combining ibogaine and 5-MeO-DMT, led to significant reductions in PTSD, depression, and anxiety symptoms. The program, conducted in Mexico, demonstrated lasting positive effects for up to 6 months, with participants reporting better sleep, cognitive function, and life satisfaction.
Abstract
Background: Research in psychedelic medicine has focused primarily on civilian populations. Further study is needed to understand whether these tre...
Human brain effects of DMT assessed via EEG-fMRI.
Proceedings of the National Academy of Sciences of the United States of America – March 28, 2023
Summary
Dimethyltryptamine (DMT), a powerful psychedelic found naturally in ayahuasca, dramatically alters consciousness by acting on serotonin receptors in the brain. Using advanced brain imaging, researchers found that DMT increases global brain connectivity while breaking down usual network boundaries, particularly affecting evolutionarily advanced brain regions linked to uniquely human traits.
Abstract
Psychedelics have attracted medical interest, but their effects on human brain function are incompletely understood. In a comprehensive, within-sub...
The Clinical Applications of Psilocybin Therapies and Post-COVID Syndrome: A Comprehensive Narrative Review
Cureus – June 24, 2025
Summary
Psilocybin, a psychedelic compound, offers hope for mental health challenges stemming from the 2019-20 coronavirus outbreak and COVID-19. A narrative review of medicine literature, spanning January 2020 to April 2024, indicates psilocybin's potential in treating depression and anxiety. Beyond its role in Psychedelics and Drug Studies, evidence suggests this naturally occurring alkaloid may inhibit Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protease, a finding for virology. While Complementary and Alternative Medicine Studies support its efficacy, robust clinical trials and chemical synthesis validation are needed for broader therapeutic use.
Abstract
The coronavirus variant (causing the COVID-19 disease) that led to a pandemic sent global shockwaves, resulting in long-term effects on physical, m...
Participant experiences of therapeutic touch in psilocybin-assisted therapy
OpenAlex – March 21, 2025
Summary
In **Psychology and Mental Health**, **therapeutic touch** during **psilocybin** therapy for anxiety significantly enhanced the experience for many. Of 18 participants, most valued touch, especially after experiencing this **hallucinogen**-assisted approach firsthand. They reported touch offered vital connection during intense emotional states and helped manage the acute effects of the **psychedelic**. Some even attributed direct therapeutic benefits to it. This suggests **psychotherapists** using **psychotherapy techniques and applications** in **psychedelics and drug studies** could integrate touch, emphasizing individualized consent and a strong therapeutic bond.
Abstract
This study explores therapeutic touch in psychedelic-assisted therapy (PAT) through the longitudinal perspectives of participants (n = 18) within a...
The influence of psilocybin on subconscious and conscious emotional learning
iScience – May 19, 2024
Summary
A compelling finding in Psychedelics and Drug Studies reveals that a 20 mg dose of psilocybin, a compound rooted in Chemical synthesis and alkaloids, significantly improved learning rates over placebo. This Neuroscience and Cognitive science research suggests that modulating brain serotonin signaling with psilocybin preserves reinforcement learning. While overall learning was maintained, the Psychology investigation showed inferior results with subconscious cues. Conversely, conscious neutral cues sometimes led to better outcomes. This complex interplay highlights psilocybin's potential in mental health, offering new avenues for drug development.
Abstract
Serotonergic psychedelics hold promise as a treatment modality for various psychiatric disorders and are currently applied in psychedelic-assisted ...
Predictors of Medical Students' Perceptions of Psilocybin-Assisted Therapy for Use in Medical Practice.
Cureus – April 01, 2023
Summary
Medical students who know more about magic mushrooms are more likely to support their therapeutic use. A survey of 213 future doctors revealed that those with greater knowledge of psilocybin and support for its legalization had more positive views about using it in mental health and palliative care. Despite psilocybin's current status as a schedule 1 drug, medical education may need to evolve as alternative medicine gains acceptance.
Abstract
Background Psilocybin use, along with other psychedelics, has seen an increased interest among professionals in the medical community due to its po...
Psilocybin-assisted psychotherapy as a potential treatment for eating disorders: a narrative review of preliminary evidence
Trends in Psychiatry and Psychotherapy – May 01, 2023
Summary
Eating disorders, marked by severe distress and cognitive inflexibility, often lack effective treatments. Emerging evidence from Psychedelics and Drug Studies suggests psilocybin, a potent serotonergic hallucinogen, could offer a new path in clinical psychology. This medicine, leveraging its neurotransmitter receptor influence on behavior, may help individuals with eating disorders overcome rigid thought patterns, improving cognition. Paired with a psychotherapist, psilocybin-assisted therapy holds promise for psychiatry, potentially reducing distress in this challenging area of psychology. Preliminary results warrant rigorous trials.
Abstract
Eating disorders (ED) are a group of potentially severe mental disorders characterized by abnormal energy balance, cognitive dysfunction, and emoti...
Psilocybin for Depression: From Credibility to Feasibility, What’s Missing?
Pharmaceuticals – December 31, 2022
Summary
Psilocybin shows significant promise for alleviating depressive symptoms, suggesting a powerful new direction in Psychiatry and Medicine. However, establishing its full Credibility requires addressing current limitations in Psychedelics and Drug Studies. Early findings often stem from small sample sizes and face challenges like blinding and limited follow-up. Standardized protocols are crucial to understand this potent compound, an alkaloid from Chemical synthesis. Future research, leveraging robust Data science, must clarify Psilocybin's real potential as a therapeutic molecule for Depression and other psychological conditions, ensuring diverse academic research themes contribute to its safe and effective application.
Abstract
Psilocybin has been suggested as a promising transdiagnostic treatment strategy for a wide range of psychiatric disorders. Recent findings showed t...
Getting in Touch with Touch: The Importance of Studying Touch in MDMA-Assisted Therapy and the Development of a New Self-Report Measure.
Psychedelic medicine (New Rochelle, N.Y.) – March 01, 2024
Summary
Touch plays a vital role in MDMA-assisted therapy, yet its effects have rarely been measured systematically. A new assessment tool, the Touch Outcomes Measurement Inventory, helps therapists understand how physical contact impacts clients during psychedelic-assisted therapy sessions. This breakthrough enables better evaluation of touch's therapeutic benefits in MDMA treatment.
Abstract
MDMA-assisted therapy (MDMA-AT) is an emerging treatment modality, with recent phase 3 trials indicating its potential for regulatory approval. Cen...